Valuation: PREDILIFE

Market Cap 4.54M 5.25M 4.24M 3.89M 7.31M 499M 7.43M 49.72M 19.52M 250M 19.7M 19.27M 827M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 9.32M 10.77M 8.7M 7.98M 15.01M 1.02B 15.25M 102M 40.06M 514M 40.44M 39.56M 1.7B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-4.17%
1 week-4.17%
Current month-4.17%
1 month-45.24%
3 months-61.41%
6 months-64.06%
Current year-61.79%
1 week 1.15
Extreme 1.15
1.2
1 month 0.9
Extreme 0.9
1.9
Current year 0.9
Extreme 0.9
4
1 year 0.9
Extreme 0.9
4
3 years 0.9
Extreme 0.9
24
5 years 0.9
Extreme 0.9
24
10 years 0.9
Extreme 0.9
24
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap.
7/27/23 Buy

Chief Executive Officer

1,200 0.0328%
3/23/22 Sell

Chief Executive Officer

3,000 0.0820%
3/9/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%-4.17%-65.98%-80.00% 5.25M
+5.64%+10.46%+98.80%+272.09% 3.98B
+2.32%+1.94%+70.59%+90.48% 3.8B
+2.09%+55.77%+140.15%-10.07% 2.87B
+4.20%+6.82%+286.83%+332.31% 2.42B
+4.99%+4.72%-25.28%-32.77% 2.27B
+2.20%0.00%+5.49% - 1.26B
-0.32%-5.18%+207.65%-43.47% 919M
+0.70%+7.43%-3.67%+25.65% 934M
+3.09%+3.92%-37.86%-5.07% 532M
Average +2.07%+8.27%+67.67%+61.02% 1.9B
Weighted average by Cap. +3.34%+12.81%+98.65%+118.83%

Financials

2024 2025
Net sales 493K 570K 461K 423K 795K 54.26M 807K 5.4M 2.12M 27.2M 2.14M 2.09M 89.92M 836K 966K 781K 716K 1.35M 91.96M 1.37M 9.16M 3.59M 46.09M 3.63M 3.55M 152M
Net income -4.26M -4.93M -3.98M -3.65M -6.87M -469M -6.98M -46.73M -18.34M -235M -18.51M -18.11M -778M -3.93M -4.55M -3.67M -3.37M -6.34M -433M -6.44M -43.11M -16.92M -217M -17.08M -16.71M -717M
Net Debt 3.54M 4.09M 3.3M 3.03M 5.7M 389M 5.79M 38.77M 15.22M 195M 15.36M 15.02M 645M 4.78M 5.52M 4.46M 4.09M 7.7M 526M 7.82M 52.35M 20.55M 263M 20.74M 20.29M 871M
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
26-08-07 €1.150 -4.17% 823
26-08-06 €1.200 0.00% 0
26-08-05 €1.200 0.00% 0
26-08-04 €1.200 0.00% 258
26-08-03 €1.200 0.00% 0

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALPRE Stock